The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA

Frank W. Roemer, C. Kent Kwoh, Daichi Hayashi, David T. Felson, Ali Guermazi

Research output: Contribution to journalReview articlepeer-review

57 Scopus citations


Currently, no disease-modifying osteoarthritis drugs (DMOADs) have been approved. Past clinical trials have failed for several reasons, including the commonly applied definition of eligibility based on radiographic assessment of joint structure. In the context of precision medicine, finding the appropriate patient for a specific treatment approach will be of increasing relevance. Phenotypic stratification by use of imaging at the time of determining eligibility for clinical trials will be paramount and cannot be achieved using radiography alone. Furthermore, identification of joints at high risk of rapid progression of osteoarthritis is needed in order to enable a more efficient DMOAD trial design. In addition, joints at high risk of collapse need to be excluded at screening. The use of MRI might offer advantages over radiography in this context. Technological advances and simplified image assessment address many of the commonly perceived barriers to the application of MRI to assessment of eligibility for DMOAD clinical trials.

Original languageEnglish (US)
Pages (from-to)372-380
Number of pages9
JournalNature Reviews Rheumatology
Issue number6
StatePublished - Jun 1 2018

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA'. Together they form a unique fingerprint.

Cite this